Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New triple diabetes pill tested in healthy adults

NCT ID NCT07399470

Knowledge-focused Sponsor: LG Chem Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study looks at how a new pill that combines three diabetes medicines (gemigliptin, dapagliflozin, and metformin) works in healthy adults. About 58 people will take either the new combination pill or the three drugs separately, then switch. The goal is to see if the combination pill works the same way in the body. This is a Phase 1 trial, so it focuses on safety and how the drug is processed, not on treating a disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

58 people

The number who actually took part.

Started

Jan 2026

Finished

Feb 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adults between 19 and 50 years of age * People with a body weight within a healthy range * People who do not have serious medical conditions and have been generally healthy in recent years * People whose screening tests (blood tests, urine tests, vital signs, ECG, etc.) show no significant abnormalities * Women of childbearing potential must not be pregnant at screening * Participants must agree to use reliable contraception or abstain from sexual activity during the study and for a short period after the last dose * People who fully understand the study, agree to follow study requirements, and provide written informed consent Exclusion Criteria: * People with a history of significant diseases, such as heart, liver, kidney, lung, neurological, psychiatric, immune, or cancer-related conditions * People with digestive diseases or surgeries that may affect how medicines are absorbed * People with abnormal screening laboratory results, especially related to liver or kidney function * People who drink large amounts of alcohol, use drugs, or smoke heavily * People who have recently taken certain medications, herbal products, or dietary supplements that could interfere with the study * People who have recently participated in another clinical trial, donated blood, or received a blood transfusion * Pregnant or breastfeeding women * People with unstable or serious health conditions that could increase risk or affect study results * Anyone who, in the opinion of the study doctor, is not suitable to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fasting conditions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fasting conditions Healthy volunteers

Contacts and locations

Locations

  • Jeonbuk National University Hospital

    Jeonju, Jeollabuk-do, 54907, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.